Stock Analysis
Top Insider-Owned Growth Companies On Euronext Paris July 2024
Reviewed by Simply Wall St
Amid a backdrop of heightened political uncertainty and fluctuating market indices, France's economic landscape presents both challenges and opportunities as it approaches a significant election. In such times, growth companies with high insider ownership on Euronext Paris stand out as potentially resilient investments, reflecting strong alignment between company management and shareholder interests.
Top 10 Growth Companies With High Insider Ownership In France
Name | Insider Ownership | Earnings Growth |
VusionGroup (ENXTPA:VU) | 13.5% | 25.2% |
Groupe OKwind Société anonyme (ENXTPA:ALOKW) | 24.8% | 30.8% |
Adocia (ENXTPA:ADOC) | 12.1% | 104.5% |
OSE Immunotherapeutics (ENXTPA:OSE) | 25.6% | 79.3% |
Icape Holding (ENXTPA:ALICA) | 30.2% | 26.1% |
Arcure (ENXTPA:ALCUR) | 21.4% | 42.4% |
La Française de l'Energie (ENXTPA:FDE) | 20.1% | 31.9% |
S.M.A.I.O (ENXTPA:ALSMA) | 17.3% | 35.2% |
Munic (ENXTPA:ALMUN) | 29.4% | 150% |
MedinCell (ENXTPA:MEDCL) | 16.4% | 72.7% |
Let's explore several standout options from the results in the screener.
MedinCell (ENXTPA:MEDCL)
Simply Wall St Growth Rating: ★★★★★☆
Overview: MedinCell S.A. is a French pharmaceutical company that specializes in developing long-acting injectable medications across multiple therapeutic areas, with a market capitalization of approximately €410.34 million.
Operations: The company generates its revenues primarily from the pharmaceuticals segment, totaling €11.95 million.
Insider Ownership: 16.4%
Earnings Growth Forecast: 72.7% p.a.
MedinCell, a French biotech company, is navigating a challenging growth trajectory with significant insider ownership. Despite recent setbacks in clinical trials, such as the Phase 3 trial for F14 not meeting its primary endpoint, there are positive signs like the substantial improvements in secondary endpoints and safety profiles consistent with earlier studies. The company's revenue is growing rapidly at 43.4% per year, outpacing the French market significantly. MedinCell's collaboration with AbbVie could inject up to €1.9 billion in milestone payments, enhancing its financial prospects despite current underperformance in fair value estimation and shareholder dilution over the past year.
- Delve into the full analysis future growth report here for a deeper understanding of MedinCell.
- The analysis detailed in our MedinCell valuation report hints at an inflated share price compared to its estimated value.
OVH Groupe (ENXTPA:OVH)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: OVH Groupe S.A. is a global provider of public and private cloud services, shared hosting, and dedicated server solutions, with a market capitalization of approximately €1.13 billion.
Operations: OVH Groupe S.A. generates revenue through three primary segments: Public Cloud (€169.01 million), Private Cloud (€589.61 million), and Web Cloud (€185.43 million).
Insider Ownership: 10.5%
Earnings Growth Forecast: 101.5% p.a.
OVH Groupe, a French cloud services provider, is poised for notable growth with high insider ownership. It's expected to turn profitable within three years, with earnings projected to surge significantly. Although its revenue growth of 10.9% per year is modest compared to the broader market, recent innovations like the launch of ADV-Gen3 Bare Metal servers underscore its commitment to technological advancement and market competitiveness. However, challenges such as a highly volatile share price and low forecasted return on equity could temper investor enthusiasm.
- Navigate through the intricacies of OVH Groupe with our comprehensive analyst estimates report here.
- Insights from our recent valuation report point to the potential overvaluation of OVH Groupe shares in the market.
VusionGroup (ENXTPA:VU)
Simply Wall St Growth Rating: ★★★★★★
Overview: VusionGroup S.A. specializes in offering digitalization solutions for commerce across Europe, Asia, and North America, with a market capitalization of €2.15 billion.
Operations: VusionGroup S.A. generates its revenue primarily through the installation and maintenance of electronic shelf labels, amounting to €801.96 million.
Insider Ownership: 13.5%
Earnings Growth Forecast: 25.2% p.a.
VusionGroup S.A. stands out in the French market with its substantial revenue growth forecast at 21.9% annually, significantly outpacing the broader market's 5.7%. This growth is complemented by a strong earnings projection, expected to increase by 25.2% each year. Despite a highly volatile share price recently, analysts remain optimistic, predicting a 44.6% potential increase in stock price. The company also demonstrated robust financial performance last year, with sales jumping to €801.96 million from €620.86 million and net income rising to €79.77 million from €18.95 million previously.
- Click here and access our complete growth analysis report to understand the dynamics of VusionGroup.
- Upon reviewing our latest valuation report, VusionGroup's share price might be too optimistic.
Key Takeaways
- Click through to start exploring the rest of the 19 Fast Growing Euronext Paris Companies With High Insider Ownership now.
- Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're helping make it simple.
Find out whether MedinCell is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About ENXTPA:MEDCL
MedinCell
A pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
High growth potential with worrying balance sheet.